Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Homeless people, incarcerated individuals and people with mental health conditions achieved a high cure rate.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.
Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.
A recent study found that providing opioid use disorder treatment was associated with a high hep C cure rate and less drug use.
There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.
Treatment for hep C has improved greatly over the past decades, with medications that treat more than one virus strain at the same time.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
The drug can quickly reverse opioid-driven overdoses.
Past research has found that proton pump inhibitors and histamine H2 agonists are associated with lower levels of certain hep C drugs.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
These drugs are approved to treat all six major genotypes of hepatitis C.
This from a real-world analysis of people treated for hep C in the United States.
The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.
The subscription-based model is the first of its kind.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.